Navigation Links
Newly-defined factors may prevent postpartum smoking relapse
Date:8/27/2008

CHAPEL HILL Although many women quit smoking during pregnancy to protect their unborn children from the effects of cigarettes, half of them resume the habit within a few months of giving birth.

By shedding light on the factors that enable the other half to put down that cigarette for good, a study by researchers at the University of North Carolina at Chapel Hill could lead to programs designed to help women quit and stay quit.

According to the study, women with a live-in partner who shared some of the burden of child-rearing were more likely to remain smoke free, while women who were single mothers or who lacked the social and financial resources to deal with being a new parent were more likely to relapse.

"In the future we can look at these and other factors in women who quit smoking during pregnancy to assess who is at low or high risk of relapse," said Carol E. Ripley-Moffitt, MDiv, research associate in UNC's department of family medicine and the study's lead author. "We can then offer more intensive interventions for those at higher risk to address the physical, behavioral and social issues related to relapse."

Smoking during pregnancy increases the risks of pregnancy complications, decreased birth weight and SIDS (Sudden Infant Death Syndrome), Ripley-Moffitt said. She noted that the past 15 years have seen a steady decrease in the number of women who smoke while pregnant, in part because of an overall decline in smoking rates among all women of childbearing age and in part because of interventions targeting women during the prenatal period.

"But more needs to be done because over 50 percent of women who quit the habit during pregnancy are smoking again at six months postpartum," Ripley-Moffitt said.

The UNC study, which appears in the August issue of the journal Nicotine and Tobacco Research, is the first to examine not only the factors leading to relapse but also those leading to a smoke-fr
'/>"/>

Contact: Stephanie Crayton
scrayton@unch.unc.edu
919-966-2860
University of North Carolina School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Study, meta-analysis examine factors associated with death from heatstroke
3. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
4. Severe heart defect likely caused by genetic factors
5. Aggressively Treating Cardiac Risk Factors May Reverse Ischemia
6. Largest Study Ever to Investigate Risk Factors of Autism and Other Developmental Disabilities Will Begin Enrolling Families in Bay Area and Across U.S.
7. Age, burden, divorce and heavy tea consumption are significant risk factors for erosive esophagitis
8. Cell Addiction to Growth Factors May Help Spur Cancers
9. Study examines factors associated with survival in advanced laryngeal cancer
10. Cardiovascular disease death rates decline, but risk factors still exact heavy toll
11. Human factors researchers test voting systems for seniors that can improve voting accuracy and speed

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...s may reduce future disease burden, researchers sa...- Encouraging city dwellers to walk and bicycle in...c health benefits than increased used of low-emiss...e study compared the projected health effects in 2...for London, England, and Delhi, India: business-a...
(Date:11/27/2009)...urers who use medical load cells at the heart of t...inging in technology partner Flintec early in the ...edical manufacturers are calling in Flintec load c..., ensuring that progress will not be constrained b...d technology. , (PRWEB) N...
(Date:11/26/2009)...date (TM) has been shown in studies to be effectiv...used by an overload of copper, and certain metasta...ver, is known about how the drug works at the mole...niversity researchers now has provided an invaluab...nd to copper-loaded metallochaperones. The drug se...
(Date:11/26/2009)...ental (RTDental), a leading dental group practice ...ansion of its services to include LUMINEERS by a c... , Durham, NC (PRWEB) -- R...t Dr. Doug Macmillan, an experienced LUMINEERS D...training seminar. RTDental’s ability to ful...
(Date:11/25/2009)...Newswire-FirstCall/ -- Onyx Pharmaceuticals, Inc...y will host two investor events in December: ,,... a.m. CT/10:00 a.m. ET ,, Principal investiga...arfilzomib in relapsed and/or refractory multiple ...of Hematology (ASH) Annual Meeting and Exposition ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...Omnicell,Inc. (Nasdaq: OMCL ), a leading provider...s, announced today that it has completed its $40.0...n Stock. A total of,2,133,898 shares were repurcha...g patient safety and operational efficiency in,hea...
...ll Changes Can Have a Big Effect on ..., N.J., March 12 Chef, nutritionist,and cookbook ...ncouraging,people with type 2 diabetes to recogniz... & Co., Inc., Chef LaLa will be,visiting selected ...
..."Superheroes" Theme, WASHINGTON, March 12 The U.... for Healthcare Research and Quality,(AHRQ) joined...anish-language national public service campaign de...ing their doctor for,regular screenings., Hispani...
...Guidance, SUNNYVALE, Calif., March 12 Cepheid (N...website, http://www.cepheid.com, ,comments on a s...ican,Medical Association regarding MRSA screening ...lion and net income,excluding stock compensation e...
...armaceuticals, a division of Wyeth (NYSE: WYE ), ...tional clinical studies to address questions from,... (CHMP) regarding the,risk-benefit profile of desv...venlafaxine for the treatment of,vasomotor symptom...
... March 11,more than 300 individuals with lupus, th...rs of Congress to increase government funding for,...will greatly expand,federal efforts on lupus. The ... lawmakers to increase funding for biomedical rese...
Other Medicine News:Health News:Omnicell Announces Completion of Its Common Stock Repurchase Plan 2Health News:Chef LaLa to Provide Healthy Menu Makeovers 2Health News:Chef LaLa to Provide Healthy Menu Makeovers 3Health News:Chef LaLa to Provide Healthy Menu Makeovers 4Health News:Chef LaLa to Provide Healthy Menu Makeovers 5Health News:AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care 2Health News:AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care 3Health News:AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care 4Health News:Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association 2Health News:Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association 3Health News:More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 2Health News:More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 3Health News:Lupus Advocates Urge Increased Funding for Lupus Research and Education 2
(Date:11/27/2009)..., Nov. 27 ACUO TECHNOLOGIES, devel... software, data migration tools and services, is p...nd Trademark Office has approved a patent applicat...mputer Network." Acuo Technologies is pleased to a...l property. In general, the granted patent applica...
(Date:11/25/2009)...o., Nov. 25 Heska Corpor...advanced diagnostic and specialty products to the ...th Roche Diagnostics Corporation for the supply of... the veterinary market. ,, (Logo: http://w..., "Heska and Roche share the same passion for i...
(Date:11/25/2009).... 25 BioTrends Research Group, Inc...telara report, the first in a multi-phase syndic...f Centocor Ortho-Biotech,s Stelara, from product l.... Each wave of the report provides quantitative i...tative information from a subset of 20. The repor...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Healthcare and Abortion 3A Randall Terry Leads Protests and Press Conferences in 10 Cities in Five States 54976 1Healthcare and Abortion 3A Randall Terry Leads Protests and Press Conferences in 10 Cities in Five States 54976 2American Red Cross Provides Safety Tips for Rip Tides Caused by Hurricane Bill 54972 1American Red Cross Provides Safety Tips for Rip Tides Caused by Hurricane Bill 54972 2ESC Congress 2009 media alert 54968 1ESC Congress 2009 media alert 54968 2
...ytic product, WOBURN, Mass., April 22 BioVex Inc...e treatments for cancer and the prevention,of infe... and Drug,Administration (FDA) has approved the de...l evaluating its lead product, OncoVEX(GM-CSF) in,...ma. The agreement was,made under the Special Proto...
...tional Institutes of Health Small, Business Inno...2 Trial, HOUSTON, April 22 Agennix, Inc. announc...e-blind, placebo-controlled Phase 2 study,of oral ... This is the,first clinical trial of talactoferrin...ction of talactoferrin, and promising preclinical ...
Other Medicine Technology:BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 2BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO 3Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 2Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 3Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 4Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 5
Universal Wrist/Forearm Splint
...ist is a custom wrist orthotic designed to limit t...s maximum range-of-motion. , ,Indications: , Wri...-triangular fibrocartilage complex , Coles fract...ial tendon rupture , ORIF - Open reduction and i...
Contoured Wrist/Forearm
Westport Lacing Wrist Brace
Medicine Products: